No Data
No Data
DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 30 percent increase over losses of $
Diamedica Therapeutics Files Key SEC Report
DiaMedica Therapeutics | 10-Q: Quarterly report
Diamedica Therapeutics 1Q Loss/Shr 14c >DMAC
Diamedica Therapeutics 1Q Loss/Shr 14c >DMAC
Press Release: DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 MINNEAPOLIS--(BUSINESS WIRE)--May 02, 2024-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC
Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
No Data